Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Explore this paper's citation graph
Summary
The ORR for SCAI was significantly higher than that for LCBI, indicating that anti–PD‐1/PD‐L1 inhibitors could make tumors more vulnerable to subsequent chemotherapy.
- Type
- article
- Published
- 2018-01-01
- Cited by
- 170
- References
- 16
- Access
- Open access
- OpenAlex
- https://openalex.org/W2765962239
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:34123460
Keywords
Medicine, Lung cancer, Chemotherapy, Immunotherapy, Internal medicine
References
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
- Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- Chemoimmunotherapy: reengineering tumor immunity
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
- Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
- Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.
- Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Cited by
- Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series
- Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
- Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
- CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study
- Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
- Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer
- Progression‐free survival and one‐year milestone survival as surrogates for overall survival in previously treated advanced non‐small cell lung cancer
- Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells
- Novel patterns of response under immunotherapy
- The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma
- Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
- Nivolumab-refractory patients with advanced non-small-cell lung cancer.
- Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease
- Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
- Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
- Combining conventional therapy with immunotherapy: A risky business?
- Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
Related papers
- Molecular Epidemiology of Female Lung Cancer
- The regional association between bronchiectasis and lung cancer in chest CT
- Electrochemical biosensors for the detection of lung cancer biomarkers: A review.
- The Expression and Clinical Significance of Adrenomedulin in Patients with Lung Cancer
- Chemoprevention of lung cancer.
- 肺癌的性别差异及机制
- Sapporo cancer seminar: membrane-associated alterations in cancer--biochemical strategies against cancer.
- Molecular genetics of lung cancer in people who have never smoked.
- Progress of DN Treg cells in immunotherapy